Latest News

Real World Study Data - Pronova

Pronova Real World Data of 1315 patients from three registries EMPIRE, EURONOVA & INNOVA was presented in TCT 2006. The 6-7 months results from the study is very encouraging and has shown very low rate of restenosis in the complex patient cohort.


Indian Heart Journal Publishes EMPIRE registry with Pronova SES in Real World patients conducted at Escorts Heart & Research Institute, New Delhi exhibiting good outcomes at 6-8 months angiographic and clinical followup.

Stenting just the left main stem gives equivalent results

Due to the elevated markers, the prolonged procedure time and the increased volume of contrast used, it is probably wise to use the simpler strategy. It's not prohibitive to take the complex approach however, because both procedures had the same, excellent clinical outcome.

Moving Biotechnology Closer To Replacing Electronic Pacemakers

UC Davis researchers have successfully used a custom designed protein and gene delivery system to restore normal heart rhythms in pigs with electronic pacemakers, reducing their dependence on implanted devices. This work suggests that scientists are one step closer to making bioengineering a reality in treating subjects affected by irregular heartbeats.

Subcutaneous UFH may be possible for acute VTE

Subcutaneous injection of unfractionated heparin (UFH) delivered in weight-adjusted, fixed doses may be as effective as low molecular weight heparin (LMWH) for the treatment of acute venous thromboembolism (VTE), trial findings suggest.